Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/INCY
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Incyte Corporation (INCY) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Incyte (INCY) trades at $126.93, up 1.83% on the day, with a bullish technical signal and strong fundamentals. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, and profitability metrics like a 27.71% net margin and 30.67% ROE are robust. Recent news highlights pipeline expansion and a post-JAKAFI growth strategy targeting $4 billion in non-JAKAFI sales. The stock is near its pivot point of $126, with resistance at $128 and support at $125.
The outlook is positive, driven by earnings beats, a diversified pipeline, and analyst consensus favoring a buy rating with a $130.07 price target. Key risks include reliance on JAKAFI, competitive pressures, and execution of growth plans. Investors should weigh strong cash flow and valuation multiples against potential volatility from clinical setbacks or market sentiment shifts.
Read full analysis

Key Stats

  • Market Cap
    $25.71B
  • Volume
    1,636,958
  • Sector
    Health
  • 52W High
    $129.93
  • 52W Low
    $81.66
  • Typical Hold Time
    32 Days
  • Enterprise Value
    $21.21B
  • Div Yield
    -
  • Trading Activity
    -
$128.65
52W Low: $81.66
25 Sep 2025
52W High: $129.93
28 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $81.66 and a high of $129.93, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Most Recent News

Content is generated by Aura AI

Cybersecurity stocks surge as AI risks prompt urgent demand for protection solutions.

Following warnings from Anthropic and OpenAI about AI systems acting unpredictably, U.S. cybersecurity stocks like Palo Alto Networks and Fortinet jumped significantly. Investors see a growing business opportunity in securing AI agents, with companie...

Market News
4 hours ago
24/7 Wall Street
Bullish
news icon
Cybersecurity stocks surge as AI risks prompt urgent demand for protection solutions.

Medical Properties Trust nets $680M in Q3 from hospital sales, showing strong asset value and plans to reduce debt.

Medical Properties Trust (MPT) generated $680 million in cash proceeds in Q3 from selling hospitals and Infracore assets, achieving gains of 60–72% over original investments. This demonstrates MPT's ability to monetize assets above book value, which ...

Market News
4 hours ago
Seeking Alpha
Bullish
news icon
Medical Properties Trust nets $680M in Q3 from hospital sales, showing strong asset value and plans to reduce debt.

WHLR jumps 191%, ARTL rises on obesity drug patent news, FSLY and IPDN also surge

Wheeler REIT (WHLR) surged 190.91% after a 1-for-9 reverse stock split, though no new catalyst was confirmed. Artelo Biosciences (ARTL) rose 74% following a provisional patent application for its obesity drug candidate ART27.13, based on early mouse ...

Market News
4 hours ago
Andrew Wynn
Bullish
news icon
WHLR jumps 191%, ARTL rises on obesity drug patent news, FSLY and IPDN also surge
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $25.71B
  • Volume
    1,636,958
  • Sector
    Health
  • 52W High
    $129.93
  • 52W Low
    $81.66
  • Typical Hold Time
    32 Days
  • Enterprise Value
    $21.21B
  • Div Yield
    -
  • Trading Activity
    -
$128.65
52W Low: $81.66
25 Sep 2025
52W High: $129.93
28 Jul 2026

Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $81.66 and a high of $129.93, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!